Zidovudine use in pregnancy and congenital malformations

AIDS

Volumn 31, Issue 12, 2017, Pages 1733-1743

  Rough, Kathryn ^a,b   Sun, Jenny W ^a,b   Seage, George R ^b   Williams, Paige L ^b   Huybrechts, Krista F ^a   Bateman, Brian T ^a   Hernandez Diaz, Sonia ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

birth defects; malformation; meta analysis; pregnancy; safety; zidovudine

Indexed keywords

ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; ARTICLE; CONGENITAL HEART MALFORMATION; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART SINGLE VENTRICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE GENITAL TRACT MALFORMATION; META ANALYSIS; MOTHER CHILD RELATION; PATENT DUCTUS ARTERIOSUS; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ADOLESCENT; ADULT; CHEMICALLY INDUCED; CHILD; DRUG INDUCED MALFORMATION; INFANT; MIDDLE AGED; NEWBORN; PREGNANCY COMPLICATION; YOUNG ADULT;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHILD; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT; ZIDOVUDINE;

EID: 85019553693     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001549     Document Type: Article

References (50)

1. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 2016; 375:1726-1737.
2. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defici Syndr 2002; 29:484-494.
3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization; 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/[Accessed 16 September 2016]
4. Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med 2014; 11:e1001635.
5. Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 2010; 29:721-727.
6. Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofenson L, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med 2011; 39:163-170.
7. Sibiude J, Le Chenadec J, Bonnet D, Tubiana R, Faye A, Dollfus C, et al. In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial. Clin Infect Dis 2015; 61:270-280.
8. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 2015; 169:48-55.
9. Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2007; 44:299-305.
10. Phiri K, Hernandez-Diaz S, Dugan KB, Williams PL, Dudley JA, Jules A, et al. First trimester exposure to antiretroviral therapy and risk of birth defects. Pediatr Infect Dis J 2014; 33:741-746.
11. Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todros T, Crepaldi A, et al., Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 2013; 120:1466-1475.
12. Vannappagari V, Albano JD, Koram N, Tilson H, Scheuerle AE, Napier MD. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry. Eur J Obs Gynecol Reprod Biol 2016; 197:6-10.
13. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998; 12:1805-1813.
14. Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, Scott GB, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012; 31:164-170.
15. Tariq S, Townsend CL, Cortina-Borja M, Duong T, Elford J, Thorne C, et al. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009. J Acquir Immune Defic Syndr 2011; 57:326-333.
16. National Governors Association. 2014 Maternal and Child Health Update: States are Using Medicaid and CHIP to Improve Health Outcomes for Mothers and Children. Washington, D.C; 2015. http://www.nga.org/files/live/sites/NGA/files/pdf/MCHUPDATE2014.PDF [Accessed 16 October 2016]
17. Palmsten K, Huybrechts KF, Mogun H, Kowal MK, Williams PL, Michels KB, et al. Harnessing the medicaid analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations. PLoS One 2013; 8:e67405.
18. Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014; 370:2397-2407.
19. Desai RJ, Huybrechts KF, Hernandez-Diaz S, Mogun H, Patorno E, Kaltenbach K, et al. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ 2015; 350:h2102.
20. Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Maeda A, et al. Late pregnancy beta blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics 2016; 138:e20160731-e20160731.
21. Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 2016; 73:938.
22. Margulis AV, Palmsten K, Andrade SE, Charlton RA, Hardy JR, Cooper WO, et al. Beginning and duration of pregnancy in automated healthcare databases: review of estimation methods and validation results. Pharmacoepidemiol Drug Saf 2015; 24:335-342.
23. Schneeweiss S, Avorn J. A review of uses of healthcare utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58:323-337.
24. Palmsten K, Huybrechts KF, Kowal MK, Mogun H, Hernández-Díaz S. Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiol Drug Saf 2014; 23:646-655.
25. Bateman BT, Mhyre JM, Hernandez-Diaz S, Huybrechts KF, Fischer MA, Creanga AA, et al. Development of a comorbidity index for use in obstetric patients. Obs Gynecol 2013; 122:957-965.
26. Bergstralh E, Kosanke J. Gmatch SAS macro. 1995. http://www.mayo.edu/research/departments-divisions/departmenthealth-sciences-research/division-biomedical-statistics-informa tics/software/locally-written-sas-macros
27. AustinPC.Optimal caliper widths for propensity-scorematching when estimating differences inmeans and differences in proportions in observational studies. Pharm Stat 2011; 10:150-161.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
31. StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp.; 2013.
32. Sterne JAC, Harris RJ, Harbord RM, Steichen TJ. Meta-analysis in Stata: an updated collection from the Stata Journal. 2nd ed. College Station, TX: StataCorp LP; 2016.
33. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia:Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
34. Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002; 155:176-184.
35. Newschaffer CJ, Cocroft J, Anderson CE, Hauck WW, Turner BJ. Prenatal zidovudine use and congenital anomalies in a Medicaid population. J Acquir Immune Defic Syndr 2000; 24:249-256.
36. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009; 23:519-524.
37. Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, Ivalo SA, et al. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 2010; 53:176-185.
38. Prieto LM, González-Tomé MI, Muñoz E, Fernández-Ibieta M, Soto B, Álvarez A, et al. Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009. BMC Infect Dis 2014; 14:700.
39. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2016. Wilmington, NC; 2016
40. Penny DJ, Vick GW. Ventricular septal defect. Lancet 2011; 377:1103-1112.
41. Baskins L. Hypospadias. In: Stringer O, Mouriquand P,editors. Pediatric surgery urology: long term outcomes Cambridge, MA: Cambridge University Press; 2006. pp. 611-620.
42. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89:1602-1608.
43. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIVuninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175-183.
44. Noguera A, Fortuny C, Muñoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114:e598-e603.
45. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769-1785.
46. Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21:929-938.
47. Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, LampeM, et al., Perinatal Safety ReviewWorking Group. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 2000; 918:212-221.
48. Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, et al., PSD Consortium. Perinatal Safety Review Working Group. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children <-5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. Ann N Y Acad Sci 2000; 918:236-246.
49. Lindegren ML, Rhodes P, Gordon L, Fleming P, Perinatal Safety Review Working Group, State, Local Health Department HIV/AIDS Surveillance Programs. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000; 918:222-235.
50. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25:261-268.